|
Platelet Drug Trial in Coronary Disease Progression Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Platelet Drug Trial in Coronary Disease Progression conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Platelet Drug Trial in Coronary Disease Progression Clinical research trials and Platelet Drug Trial in Coronary Disease Progression health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Platelet Drug Trial in Coronary Disease Progression. Platelet Drug Trial in Coronary Disease Progression Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Platelet Drug Trial in Coronary Disease Progression clinical trial. Human subjects frequently get the finest healthcare available for their Platelet Drug Trial in Coronary Disease Progression condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Platelet Drug Trial in Coronary Disease Progression  Platelet Drug Trial in Coronary Disease Progression
Platelet Drug Trial in Coronary Disease Progression
For Condition: Cardiovascular Diseases,Coronary Disease,Heart Diseases,Myocardial Ischemia
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine the effectiveness of the platelet inhibitor drugs dipyridamole and aspirin in reducing the angiographic progression of coronary artery disease over a five-year period and to test the predictive value of the platelet survival half-life in identifying patients with more rapid progression of coronary disease and development of its complications.
Details: BACKGROUND: Coronary atherosclerosis is the leading cause of death in this country and the developed countries of the world. Although modern coronary care units have resulted in a markedly decreased hospital mortality from acute myocardial infarction, especially in those patients who enter the hospital early, its overall impact is limited since two-thirds of patients who die from coronary disease do not reach the hospital. When the trial was initiated in 1979, new approaches to the medical treatment of coronary disease and its complications were needed with an effort directed towards prevention of its progression and prevention of its complications through medical therapy. This prevention could save significant health care dollars over the long-term especially if the need for aortocoronary bypass graft surgery and the incidence of myocardial infarction could be reduced. Early identification of the patient at risk of developing coronary disease or of those with early coronary artery lesions would allow a greater impact of any successful intervention therapy. DESIGN NARRATIVE: Randomized, double-blind. The patients in the experimental group were treated with dipyridamole and aspirin for five years. Patients in the control group received a lactose placebo. The primary endpoint was angiographic evidence of progression of coronary artery disease and development of new coronary disease. Secondary endpoints included total mortality, cardiac mortality, mortality due to myocardial infarction, and incidence of new myocardial infarction. Recruitment ended in December 1982.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Patients aged 65 or less. Angiographically identified coronary heart disease
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 15;
Study Start Date: December 1979
Record last reviewed: January 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000496
Other Myocardial Ischemia Studies:
1. Rapid Early Action for Coronary Treatment (REACT)
2. NHLBI Type II Coronary Intervention Study
3. Women's Antioxidant and Cardiovascular Study (WACS)
4. Program on Surgical Control of Hyperlipidemias (POSCH)
5. Multicenter Investigation of Limitation of Infarct Size (MILIS)
Related Studies:
Other Myocardial Ischemia Clinical Trials
Other Clinical Trials
Other Clinical Trials
Platelet Drug Trial in Coronary Disease Progression
|
|
|
|
|
|
|
|
